Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial-Reference-Cited by-同舟云学术

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Published:2012-09 Issue:9 Volume:13 Page:879-886
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Di Giacomo Anna Maria,Ascierto Paolo A,Pilla Lorenzo,Santinami Mario,Ferrucci Pier Francesco,Giannarelli Diana,Marasco Antonella,Rivoltini Licia,Simeone Ester,Nicoletti Stefania VL,Fonsatti Ester,Annesi Diego,Queirolo Paola,Testori Alessandro,Ridolfi Ruggero,Parmiani Giorgio,Maio Michele

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma;Balch;J Clin Oncol,2001

2. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials;Korn;J Clin Oncol,2008

3. The role of radiation therapy in the management of metastatic melanoma in the brain;Hong;Int J Surg Oncol,2012

4. Current systemic therapy for metastatic melanoma;Agarwala;Expert Rev Anticancer Ther,2009

5. Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Dummer;Ann Oncol,2010

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of brain metastases response to immunotherapy with pembrolizumab;Journal of Neuro-Oncology;2024-07-04

2. Evolutionary Trend Analysis of Research on Immunotherapy for Brain Metastasis Based on Machine-Learning Scientometrics;Pharmaceuticals;2024-06-28

3. Local and Systemic Management Options for Melanoma Brain Metastases;The Cancer Journal;2024-03

4. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial;European Journal of Cancer;2024-03

5. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?;European Journal of Cancer;2024-02